Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161245 | 0.93 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL7811320 | 0.88 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL23345377 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL634085 | 0.81 | ALDH1A1 (0.79) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL15840367 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL15946356 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL14676210 | 0.80 | MMP1 (0.61) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL2408403 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL12169369 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 | |
| SCHEMBL1479992 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947712-A | Synthesis method of sulfonamide organic compound | 苏州华道生物药业股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2020-03-24 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | MOTHER'S PHARMACEUTICAL CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2000066562-A1 | PYRAZOLES HAVING ANTIINFLAMMATORY ACTIVITY | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3R5, PIK3R1, PIK3R3 | ALDH1A1 3781/4885CYP3A4 1392/4885CYP2C9 980/4885 |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | ALDH1A1 2756/4885CYP3A4 994/4885CYP2C9 378/4885 |
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | ALDH1A1 3781/4885CYP3A4 1392/4885CYP2C9 980/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | ALDH1A1 2068/4885CYP3A4 1036/4885CYP2C9 461/4885 |
| US-20170152268-A1 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | RIPK1, RIPK2, RIPK3 | ALDH1A1 3332/4885CYP3A4 4847/4885CYP2C9 4790/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | ALDH1A1 3666/4885CYP3A4 546/4885CYP2C9 879/4885 |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | ALDH1A1 2421/4885CYP3A4 598/4885CYP2C9 392/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | ALDH1A1 2438/4885CYP3A4 3675/4885CYP2C9 4527/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | ALDH1A1 1394/4885CYP3A4 658/4885CYP2C9 1042/4885 |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | ALDH1A1 3781/4885CYP3A4 1392/4885CYP2C9 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.